

Please type a plus sign (+) inside this box. **NOTED PTO/SB/08**

Substitute for form 1449/PTO JUL 3 1 2006 <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Complete if Known	
Sheet	1	of	4
Application Number		10/550,856	
Int'l Filing Date		03/24/2004	
First Named Inventor		Stephen Ludwig, et al.	
Group Art Unit		<del>Unassigned</del> 1654	
Examiner Name		<del>Unassigned</del> Julie Ha	
Attorney Docket Number		7003/45	

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Issue Date MM-DD-YYYY
		Number	Class/Subclass		

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office <sup>3</sup>	Number Class/ Subclass			

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Publication		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Class/Subclass		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
/J.H./	1.	HEIKE FESQ, et al., "Programmed Cell Death (Apoptosis) in Human Monocytes Infected by Influenza A Virus, <i>Immunobiol.</i> , 1994, vol. 190, pp. 175-182.			
/J.H./	2.	ISAMU MORI, et al., "In Vivo Induction of Apoptosis by Influenza Virus", <i>Journal of General Virology</i> , 1995, vol. 76, pp. 2869-2873.			
/J.H./	3.	TAKENORI TAKIZAWA, et al., "Induction of Programmed Cell Death (Apoptosis) by Influenza Virus Infection In Tissue Culture Cells", <i>Journal of General Virology</i> , 1993, vol. 74, pp. 2347-2355.			

Examiner Signature	/Julie Ha/	Date Considered	05/20/2008
--------------------	------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>12</sup>Unique citation designation number: \*Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box. FORM PTO/SB/08

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/550,856
		Int'l Filing Date	03/24/2004
		First Named Inventor	Stephen Ludwig, et al.
		Group Art Unit	<del>Unassigned</del> 1654
		Examiner Name	<del>Unassigned</del> Julie Ha
Sheet 2 of 4	Attorney Docket Number	7003/45	

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/J.H./	4.	HANA VAN CAMPEN, et al., "Virulent Avian Influenza A Viruses: Their Effect on Avian Lymphocytes and Macrophages <i>in vivo</i> and <i>in vitro</i> ", <i>J. Gen. Virol.</i> , 1989, vol. 70, pp. 2887-2895.	
	5.	HANA VAN CAMPEN, et al., "Destruction of Lymphocytes by a Virulent Avian Influenza A Viruses", <i>J. Gen. Virol.</i> , 1989, vol. 70, pp. 467-472.	
	6.	LARISA V. GUBAREVA, et al., "Evidence for Zanamivir Resistance in an Immunocompromised Child Infected with Influenza B Virus", <i>The Journal of Infectious Diseases</i> , 1998, vol. 178, pp. 1257-1262.	
	7.	C. SCHOLTISSEK, et al., "Failure to Obtain Drug-Resistant Variants of Influenza Virus After Treatment with Inhibiting Doses of 3-Deazaadenosine and H7", <i>Archives of Virology</i> , 1991, vol. 119, pp.111-118.	
	8.	PHILLIP D. ZAMORE, et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals", <i>Cell</i> , March 31, 2000, vol. 101, pp. 25-33.	
	9.	YUICHI WATANABE, et al., "Role of Phosphatidylserine Exposure and Sugar Chain Desialylation at the Surface of Influenza Virus-Infected Cells in Efficient Phagocytosis by Macrophages", <i>The Journal of Biological Chemistry</i> , Issue of May 17, 2002, vol. 277, no. 20, pp. 18222-18228.	
	10.	THOMAS TUSCHL, et al., Targeted mRNA Degradation by Double Stranded RNA in Vitro, downloaded from <a href="http://www.genesdev.org">www.genesdev.org</a> on April 13, 2006, pp. 3190-3197.	
/J.H./	11.	TERRANCE M. TUMPEY, et al., "Depletion of Lymphocytes and Diminished Cytokine Production in Mice Infected with a Highly Virulent Influenza A (H5N1) Virus Isolated from Humans", <i>Journal of Virology</i> , July 2000, vol. 74, no. 13, pp. 6105-6116.	

Examiner Signature	/Julie Ha/	Date Considered	05/20/2008
--------------------	------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.  
 Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and trademark Office, Washington, DC 20231.  
 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		Application Number	10/550,856
		Int'l Filing Date	03/24/2004
		First Named Inventor	Stephen Ludwig, et al.
		Group Art Unit	Unassigned 1654
		Examiner Name	Unassigned Julie Ha
Sheet	3	of	4
		Attorney Docket Number	7003/45

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/J.H./	12.	NANCY A. THORNBERRY, et al., "Caspases: Enemies Within", <i>Science</i> , August 28, 1998, vol. 281, pp. 1312-1316.	
	13.	MUNEESH TEWARI, et al., "Yama/CPP32 $\beta$ , a Mammalian Homolog of CED-3, is a CrmA-Inhibitable Protease that Cleaves the Death Substrate Poly(ADP-Ribose) Polymerase", <i>Cell</i> , June 2, 1995, vol. 81, pp. 801-809.	
	14.	STEPHAN PLESCHKA, et al., "A Plasmid-Based Reverse Genetics System for Influenza A Virus", <i>Journal of Virology</i> , June 1996, pp. 4188-4192.	
	15.	STEPHAN PLESCHKA, et al., "Influenza Virus Propagation is Impaired by Inhibition of the Raf/MEK/ERK Signalling Cascade", <i>Nature Cell Biology</i> , March 2001, vol. 3, 7 pages.	
	16.	CHRISTOPHER W. OLSEN, et al., "bcl-2 Alters Influenza Virus Yield, Spread, and Hemagglutinin Glycosylation", <i>Journal of Virology</i> , January 1996, vol. 70, no. 1, pp. 663-666.	
	17.	ROBERT E. O'NEILL, et al., "The Influenza Virus NEP (NS2 Protein) Mediates the Nuclear Export of Viral Ribonucleoproteins", <i>The EMBO Journal</i> , 1998, vol. 17, no. 1, pp. 288-296.	
	18.	STEPHEN LUDWIG, et al., "Influenza Virus-Induced AP-1-Dependent Gene Expression Requires Activation of the JNK Signaling Pathway", <i>The Journal of Biological Chemistry</i> , vol. 276, no. 14, issue of April 6, 2001, pp. 10990-10998.	
/J.H./	19.	STEPHEN LUDWIG, et al., "Influenza A Virus NS1 Protein Inhibits Activation of Jun N-Terminal Kinase and AP-1 Transcription Factors", <i>Journal of Virology</i> , vol. 76, no. 21, Nov. 2002, pp. 11166-11171.	

Examiner Signature	/Julie Ha/	Date Considered	05/20/2008
--------------------	------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.  
 Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and trademark Office, Washington, DC 20231.  
 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box. FORM PTO/SB/08

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Complete if Known			
		Application Number	10/550,856		
		Int'l Filing Date	03/24/2004		
		First Named Inventor	Stephen Ludwig, et al.		
		Group Art Unit	<del>Unassigned</del> 1654		
Examiner Name	<del>Unassigned</del> Julie Ha				
Sheet	4	of	4	Attorney Docket Number	7003/45

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
/J.H./	20.	REINER U. JÄNICKE, et al., "Caspase-3 is Required for DNA Fragmentation and Morphological Changes Associated with Apoptosis", <i>The Journal of Biological Chemistry</i> , vol. 273, no.16, issue of April 17, 1998, pp. 9357-9360.		
	21.	VIRGINIA S. HINSHAW, et al., "Apoptosis: A Mechanism of Cell Killing by Influenza A and B Viruses", <i>Journal of Virology</i> , vol. 68, no. 6, June 1994, pp. 3667-3673.		
	22.	LAVINA FALEIRO, et al., "Caspases Disrupt the Nuclear-Cytoplasmic Barrier", <i>The Journal of Cell Biology</i> , vol. 151, no. 5, November 27, 2000, pp. 951-959.		
	23.	QUINN L. DEVERAUX, et al., "X-Linked IAP is a Direct Inhibitor of Cell-Death Proteases", <i>Nature</i> , vol. 388, July 17, 1997, pp. 300-304.		
	24.	GERALD M. COHEN, "Caspases: The Executioners of Apoptosis", <i>Biochem J.</i> , 1997, vol. 326, pp. 1-16.		
	25.	WEISAN CHEN, et al., "A Novel Influenza A Virus Mitochondrial Protein That Induces Cell Death", <i>Nature Medicine</i> , December 2001, vol. 7, no.12, pp. 1306-1312.		
/J.H./	26.	THIJN R. BRUMMELKAMP, et al., "A System for Stable Expression of Short Interfering RNA's in Mammalian Cells", <i>Science</i> , April 19, 2002, vol. 296, pp. 550-553.		
	27.	SIDDHARTH BALACHANDRAN, et al., "Alpha/Beta Interferons Potentiate Virus-Induced Apoptosis Through Activation of the FADD/Caspase-8 Death Signaling Pathway", <i>Journal of Virology</i> , February 2000, pp. 1513-1523.		

Examiner Signature	/Julie Ha/	Date Considered	05/20/2008
--------------------	------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.